Sun Pharma acquired established prescription brands from Novartis AG and Novartis Pharma AG (together Novartis) in Japan. In a USD 293 million cash deal Indias Sun Pharmaceutical Industries Ltd. has agreed to buy 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan, the Indian company said.
In a statement issued late Tuesday the company said that a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of USD 293 million.
"These brands have combined annualised revenues of approximately USD 160 million and address medical conditions across several therapeutic areas," the company said.
"Under the terms of the agreements, Novartis will continue to distribute these brands, for a certain period, pending transfer of all marketing authorisations to Sun Pharma's subsidiary."
The acquired brands will be marketed by a reliable and established local marketing partner under the Sun Pharma label. The partner will also be responsible for distribution of the brands.
Commenting on the acquisition, Dilip Shanghvi, Managing Director, Sun Pharma said, “Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future.”
As per the December-2015 IMS Data, the size of the Japanese pharmaceutical market was estimated at USD 73 billion, accounting for over seven percent of the USD 1 trillion global pharmaceutical market.
